|
Aug 7
|
Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Aug 7
|
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 7
|
Insmed: Q2 Earnings Snapshot
|
|
Aug 7
|
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 6
|
Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates
|
|
Aug 6
|
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
|
|
Aug 5
|
Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
|
|
Aug 4
|
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
|
|
Jul 31
|
Insmed’s Pipeline Growth With Brensocatib Approval And Phase 3 Trials
|
|
Jul 31
|
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
|
|
Jul 31
|
Strong Drug Development Momentum Lifted Insmed Incorporated (INSM) in Q2
|
|
Jul 30
|
Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.
|
|
Jul 28
|
Synthetic rescue: Insmed explores a new frontier in genetic therapeutics
|
|
Jul 24
|
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
|
|
Jul 24
|
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
|
|
Jul 17
|
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
|
|
Jul 14
|
Jim Cramer Calls Insmed “Very Speculative”
|
|
Jul 14
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 30
|
United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says
|
|
Jun 18
|
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
|